AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20356641 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal employment
Number of subjects: 0
Study 20356641 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased family income and access to public health insurance coverage
Number of subjects: 0
Study 20356641 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal employment (secondary analysis)
Number of subjects: 0
Study 17641250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN 1.2 mg for 2 hours
Number of subjects: 37
Study 17641250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythrityl tetranitrate (PETN) 80 mg
Number of subjects: 37
Study 17641250 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN) 40 mg
Number of subjects: 37
Study 17641250 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 37
Study 15738296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation during acute vasodilator test
Number of subjects: 22
Study 12376307 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-center needling therapy
Number of subjects: 78
Study 12376307 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (control group)
Number of subjects: 78
Study 9793091 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane 1400T (30 patients)
Number of subjects: 81
Study 9793091 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane 1401T (24 patients)
Number of subjects: 81
Study 9793091 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 81
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular geometric shapes of horses
Number of subjects: 0
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Silhouettes of horse shapes and enantiomorphic deltoid shapes
Number of subjects: 0
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oblique contours
Number of subjects: 0
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical orientation of deltoid shapes
Number of subjects: 0
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically oriented horse silhouettes
Number of subjects: 0
Study 8577573 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing from two positions
Number of subjects: 0
Study 2782131 — intervention group
Group type: EXPERIMENTAL
Intervention: MLAgCu250
Number of subjects: 0
Study 2782131 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 0
Study 2782131 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiloads (MLs)
Number of subjects: 0
Study 2782131 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 0
Study 1218275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 250
Study 1218275 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 250
Study 1218275 — intervention group
Group type: COMPARATOR
Intervention: Surgery + postoperative RT
Number of subjects: 250
Study 30507875 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (200 mg/kg/d)
Number of subjects: 14
Study 30507875 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (5 mg/kg/d)
Number of subjects: 14
Study 28374207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness group
Number of subjects: 0
Study 28374207 — intervention group
Group type: COMPARATOR
Intervention: Support and information group
Number of subjects: 0
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS‐9 (2.5 g)
Number of subjects: 753
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS‐9 (5 g)
Number of subjects: 753
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS‐9 (10 g)
Number of subjects: 753
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS‐9 (5 g) during maintenance phase
Number of subjects: 753
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS‐9 (10 g) during maintenance phase
Number of subjects: 753
Study 25415807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753
Study 25415807 — intervention group
Group type: COMPARATOR
Intervention: Placebo during maintenance phase
Number of subjects: 753
Study 25415807 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (ZS‐9)
Number of subjects: 753
Study 25415807 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (Placebo)
Number of subjects: 753
Study 22639824 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatally displaced canines (PDC)
Number of subjects: 1674
Study 22639824 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally displaced canines (BDC)
Number of subjects: 1674
Study 22639824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maxillary canine impaction)
Number of subjects: 1674
Study 21146765 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape from Diab and Nanoswarm: Invasion from Inner Space video games
Number of subjects: 133
Study 21146765 — intervention group
Group type: COMPARATOR
Intervention: Control group played diet and physical activity knowledge‐based games
Number of subjects: 133
Study 18718819 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon for children (CfC)
Number of subjects: 40
Study 18718819 — intervention group
Group type: COMPARATOR
Intervention: Creon 10000 (C10)
Number of subjects: 40
Study 18718819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 16825682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland meal after a bland diet (BAB)
Number of subjects: 36
Study 16825682 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili meal after a bland diet (CAB)
Number of subjects: 36
Study 16825682 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili meal after a chili-containing diet (CAC)
Number of subjects: 36
Study 14707470 — intervention group
Group type: EXPERIMENTAL
Intervention: Suckling
Number of subjects: 0
Study 10618526 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule of recombinant Hepatitis B vaccine
Number of subjects: 200
Study 10618526 — intervention group
Group type: COMPARATOR
Intervention: Traditional schedule of recombinant Hepatitis B vaccine
Number of subjects: 200
Study 10618526 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose for children with anti‐HBsAg concentrations below 10 mUI/ml
Number of subjects: 200
Study 10618526 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine administered earlier
Number of subjects: 200
Study 8859286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 units of Botulinum A exotoxin (BTX)
Number of subjects: 0
Study 8859286 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 0
Study 1517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopkins Pain Rating Instrument (HPRI)
Number of subjects: 71
Study 1517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 71
Study 1517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Descriptor Scale (VDS)
Number of subjects: 71
Study 6394890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ng prostacyclin (PGI2)/kg/min
Number of subjects: 12
Study 6394890 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 12
Study 31145188 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide area circumferential ablation (WACA)
Number of subjects: 260
Study 29880769 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS (Baby‐Led Introduction to SolidS)
Number of subjects: 206
Study 29880769 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 206
Study 26001339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg
Number of subjects: 60
Study 26001339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg
Number of subjects: 60
Study 26001339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg and 160 μg
Number of subjects: 60
Study 25034652 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain therapy for 4 weeks
Number of subjects: 43
Study 25034652 — intervention group
Group type: COMPARATOR
Intervention: Patients with FM
Number of subjects: 43
Study 25034652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecurely attached FM patients
Number of subjects: 43
Study 25034652 — intervention group
Group type: EXPERIMENTAL
Intervention: Securely attached FM patients
Number of subjects: 43
Study 25034652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels
Number of subjects: 43
Study 22898059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Top Tips (10TT) intervention
Number of subjects: 520
Study 22898059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 520
Study 20716270 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc closure of the peritoneum and fascia with Premilene suture (Group A)
Number of subjects: 191
Study 20716270 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc closure of the peritoneum and fascia with Polydioxanone suture (Group B)
Number of subjects: 191
Study 20716270 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate closure of the peritoneum and fascia with single stitches of Ethibond suture (Group C)
Number of subjects: 191
Study 17640311 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated Plasma Separation and Adsorption (FPSA)
Number of subjects: 0
Study 16336072 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent self-weighing in weight loss trial
Number of subjects: 3026
Study 16336072 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent self-weighing in weight gain prevention trial
Number of subjects: 3026
Study 16336072 — intervention group
Group type: COMPARATOR
Intervention: Control group in weight gain prevention trial
Number of subjects: 3026
Study 16336072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group in weight gain prevention trial
Number of subjects: 3026
Study 16336072 — intervention group
Group type: COMPARATOR
Intervention: Control group in weight loss trial
Number of subjects: 3026
Study 16336072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group in weight loss trial
Number of subjects: 3026
Study 12409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m(2) days 1 and 8 plus cisplatin 75 mg/m(2) day 2 every 21 days (GC arm)
Number of subjects: 612
Study 12409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m(2) (3‐hour infusion) then carboplatin (AUC 6 mg/mL x min) on day 1 every 21 days (PCb arm)
Number of subjects: 612
Study 12409326 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m(2)/wk for 12 weeks then every other week plus cisplatin 100 mg/m(2) day 1 every 28 days (VC arm)
Number of subjects: 612
Study 10334422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral coenzyme Q for 3 months
Number of subjects: 30
Study 10334422 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study 7493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20
Study 7493170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2020274 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glucose/electrolyte drink (G)
Number of subjects: 7
Study 2020274 — intervention group
Group type: COMPARATOR
Intervention: Flavored water placebo (P)
Number of subjects: 7
Study 6176791 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 40
Study 6176791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 40
Study 30159300 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ET) - 12-week downhill walking exercise on treadmill
Number of subjects: 32
Study 30159300 — intervention group
Group type: COMPARATOR
Intervention: Control group - COPD conventional medications and walking on paved surfaces
Number of subjects: 32
Study 27912935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule (BHG)
Number of subjects: 120
Study 27912935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25707709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (calibrated to achieve blood concentrations of 20, 80 and 120 mg/dL)
Number of subjects: 18
Study 25707709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 18
Study 23505170 — intervention group
Group type: EXPERIMENTAL
Intervention: Curves program (30-min exercise circuit and high-vegetable/low-fat/calorie-restricted diet) for 6 months
Number of subjects: 42
Study 23505170 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control arm (6 months of observation)
Number of subjects: 42
Study 23505170 — intervention group
Group type: EXPERIMENTAL
Intervention: Curves program (30-min exercise circuit and high-vegetable/low-fat/calorie-restricted diet) for 6 months followed by observation
Number of subjects: 42
Study 20143247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of pure oxygen
Number of subjects: 18
Study 20143247 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of air (placebo)
Number of subjects: 18
Study 17936285 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration
Number of subjects: 1069
Study 17936285 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration (early studies)
Number of subjects: 1069
Study 17936285 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration (later studies)
Number of subjects: 1069
Study 17936285 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1069
Study 16842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Awareness and Rehabilitation Training (DART)
Number of subjects: 64
Study 16842977 — intervention group
Group type: COMPARATOR
Intervention: Usual Care plus Information (UCI)
Number of subjects: 64
Study 14998561 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 8
Study 14998561 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 8
Study 10882612 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic potato (n=20)
Number of subjects: 24
Study 10882612 — intervention group
Group type: COMPARATOR
Intervention: Wild-type potato (n=4)
Number of subjects: 24
Study 9366865 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg daily)
Number of subjects: 580
Study 9366865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 1589080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg intravenously 30‐60 minutes before the operation)
Number of subjects: 75
Study 1589080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine in association with metoclopramide
Number of subjects: 75
Study 2986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole combined with postoperative radiotherapy
Number of subjects: 72
Study 2986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole in postmenopausal patients
Number of subjects: 72
Study 2986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment
Number of subjects: 72
Study 3298080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 53
Study 3298080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31729280 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim sexual orientation (bisexual, lesbian, heterosexual)
Number of subjects: 826
Study 31729280 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim sexual orientation (bisexual)
Number of subjects: 826
Study 31729280 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of victim as more promiscuous
Number of subjects: 826
Study 30499511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab, 0.05 ml, administered twice with one-month interval.
Number of subjects: 45
Study 27760796 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of resuscitation (up to 37.0 minutes)
Number of subjects: 11368
Study 27760796 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of resuscitation (30-40 minutes)
Number of subjects: 11368
Study 27760796 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation duration
Number of subjects: 11368
Study 27760796 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation duration (up to 47 minutes)
Number of subjects: 11368
Study 25552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block with 0.25% bupivacaine
Number of subjects: 45
Study 25552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound infiltration with 0.25% bupivacaine
Number of subjects: 45
Study 25552210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 21820233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative administration of oral pregabalin 75 mg
Number of subjects: 40
Study 21820233 — intervention group
Group type: COMPARATOR
Intervention: Preoperative administration of oral pregabalin 75 mg
Number of subjects: 40
Study 20151772 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (home televisits with a dietitian or nurse educator every 4-6 weeks)
Number of subjects: 0
Study 20151772 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-intervention subjects)
Number of subjects: 0
Study 20151772 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study 18093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures of fear-relevant animals (snakes and spiders)
Number of subjects: 81
Study 18093573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-relevant distracter (snake for snake fearful children)
Number of subjects: 81
Study 16999232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (specific viral-based therapies not detailed)
Number of subjects: 0
Study 16999232 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 14609895 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose intraoral administration
Number of subjects: 11
Study 10674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 148
Study 10674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 148
Study 10674411 — intervention group
Group type: COMPARATOR
Intervention: No drugs (Control)
Number of subjects: 148
Study 9172968 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg/day)
Number of subjects: 40
Study 9172968 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 40
Study 8279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed men
Number of subjects: 2106
Study 8279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed women
Number of subjects: 2106
Study 8279199 — intervention group
Group type: COMPARATOR
Intervention: Non-employed men and women
Number of subjects: 2106
Study 2879617 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion strategy
Number of subjects: 533
Study 2879617 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 533
Study 2879617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supportive therapy with beta-blockade and calcium antagonists
Number of subjects: 533
Study 2879617 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom limited bicycle stress test, radionuclide ventriculography, and 24 hour ambulatory electrocardiogram
Number of subjects: 533
Study 2879617 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous myocardial infarction or heart failure during the current episode
Number of subjects: 533
Study 31096121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 42
Study 29595562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (8 mg/d)
Number of subjects: 88
Study 29595562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g/d of lactose powder)
Number of subjects: 88
Study 26194270 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (meditation, breathing exercises, cold exposure)
Number of subjects: 0
Study 24076283 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg on admission, followed by 20 mg/day)
Number of subjects: 504
Study 24076283 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (control group)
Number of subjects: 504
Study 23107222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 49
Study 23107222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20413437 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 25
Study 18625676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan at 100 mg
Number of subjects: 0
Study 18625676 — intervention group
Group type: COMPARATOR
Intervention: Bosentan
Number of subjects: 0
Study 15319314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with bilateral periventricular leukomalacia (PVL)
Number of subjects: 0
Study 15319314 — intervention group
Group type: COMPARATOR
Intervention: Matched peers (term-born adolescents and former preterms with normal MRI scan)
Number of subjects: 0
Study 11833996 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia with Mg2+ (BC‐Mg2+, n = 200)
Number of subjects: 400
Study 11833996 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia without Mg2+ (BC, n = 200)
Number of subjects: 400
Study 10891631 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients enrolled in Project MATCH
Number of subjects: 0
Study 10891631 — intervention group
Group type: COMPARATOR
Intervention: Clients not entered into the study
Number of subjects: 0
Study 8703460 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood reinfusion
Number of subjects: 20
Study 1551535 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily before breakfast
Number of subjects: 240
Study 1551535 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 240